U.S. Food and Drug Administration approves Pfizer’s INLYTA® (axitinib)
First treatment to demonstrate superior benefit in a Phase 3…
27 January 2012 | By Pfizer
First treatment to demonstrate superior benefit in a Phase 3 study compared with another targeted agent in advanced RCC...